参考文献/References:
1 Hertz S,Robert A.Application of radioactive iodine in the rapy of Graves disease[J].J Clin Invest,1942,21:624.
2 Arbelle JE,Porath A.Practice guideline for the detection and management of thyroid dysfunction,A comparative review of the recom-mendations[J].Clin Endocrinol,1999,51(1):11-18.
3 Kuijpens JL,Hansen B,Hamming JF,et al.Trends in treatment and long-term survival of thyroid cancer in southeastern Netherlands,1960-1992[J].Eur JCancer,1998,34(8):1235-1241.
4 Hermus AR,Huysmans DA.Treatment of benign nodular thyoid dis-ease[J].N Engl J Med,1998,338(20):1438-1447.
5 Vetter RJ.Regulations for radioiodine therapy in the United States:current status and the process of change[J].Thyroid,1997,7(2):209-211.
6 Council of the European Union.Guideline 96/29/EURATOM to determine basic directions for public and workers against ionizing radiation related dangers[R].Official Journal of the European Communities,1996,L159:1-28.
7 US Nuclear Regulatory Commission.10 CFR Part 35.75:Release of individuals containing unsealed byproduct material or implants containing byproduct material[R].Washington,DC:US Government Printing Office,2000.
8 US Nuclear Regulatory Commission.Regulatory Guide 8.39:Release of patients administered radioactive materials[R].Washington,DC:NRC,1997.
9 Coover LR,Silberstein EB,Kuhn PJ,et al.Therapeutic 131I in outpatients:a simplified method conforming to the Code of Federal Regulations,title 10,part 35.75[J].J Nucl Med,2000,41(11):1868-1875.
10 Klerk JM.131I therapy:inpatient or outpatient?[J].J Nucl Med,2000,41(11):1876-1878.
11 European Commission.Radiation Protection 97:Radiation Protection Following Iodine-131 Therapy[R].Luxembourg,Belgium:Office for Official Publications of the European Commissions,1998.
12 Schicha H,Scheidhauer K.Radioiodine therapy in Europe-a survey[Article in German[J].Nuklearmedizin,1993,32(6):321-324.
13 Korber C,Schneider P,Hanscheid H,et al.Is the post-therapeutic dosimetry of patients with short-term hospitalization after 131I therapy sufficiently reliable?[J].Nuklearmedizin,2000,39(1):9-12.
14 Wellner U,Eschner W,Hillger HW,et al.Exposure of relatives of patients after stationary radioiodine therapy by inhalation of 131I in the ir homes[J].Nuklearmedizin,1998,37(3):113-119.
15 Beckers C.Regulations and policies on radioiodine I-131 therapy in European[J].Thyroid,1997,7(2):221-224.
16 Demir M,Kabasakal L,Onsel C.Evaluation of external radiation exposure rate from radioiodine-treated hyperthyroid patients and radiation safety considerations[J].Nucl Med Commun,1996,17(8):692-695.
17 Barrington SF,O’Doherty MJ,Kettle AG,et al.Radiation exposure of the families of outpatients treated with radioiodine (iodine-131)for hyperthyroidism[J].Eur J Nucl Med,1999,26(7):686-692.
18 电离辐射防护与辐射源安全基本标准[S].北京:中国标准出版社,2003.
19 中华医学会临床技术操作规范·核医学分册[S].北京:人民军医出版社,2004.
20 National Council on Radiation Protection and Measurements.NCRP Report No.37:Precaution in the management of patients who have received therapeutic amounts of radionuclides[R].Washington,DC:NCRP,1970.
21 Friedman MI,Marvin I,Ghesani M,et al.Interactive Software Automates Personalized Radiation Safety Plans for Na131I Therapy[J].Health Phys,2002,83(4):S71-S84.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[11]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):153.
[12]李诗运.131I治疗甲亢后甲减的综合预防和处理措施[J].国际放射医学核医学杂志,2004,28(4):157.
LI Shi-yun.Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):157.
[13]徐颖,徐晓辉.131I治疗甲亢后的继发甲减及替代治疗[J].国际放射医学核医学杂志,2004,28(6):265.
XU Ying,XU Xiao-hui.The secondary hypothyroidism after radioiodine therapy and the replacement treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):265.